Semax

Technical overview

Synthetic ACTH(4-10) heptapeptide nootropic / neuroprotective research peptide

Semax is a synthetic heptapeptide analogue of ACTH(4-10) with a Pro-Gly-Pro extension that improves stability relative to the native fragment. It has a long research history in Russian neuroscience for nootropic, neuroprotective, and cerebrovascular questions, with intranasal delivery as the dominant route.

Indexed studies examine brain penetration after nasal dosing, membrane binding and biodegradation, BDNF-related signaling, and clinical-research use in acute ischemic stroke settings where multi-milligram daily intranasal totals were tested. Western large-scale replication is more limited than the domestic literature base.

For dosage education, distinguish animal mcg/kg work, human stroke-trial milligram schedules, and lower-microgram nootropic research-chemical practices discussed online. Only documented literature ranges are emphasized here, under research-use-only framing.

Mechanism of action

Semax does not act like a classical long-acting endocrine ACTH drug at therapeutic glucocorticoid doses. Research points to rapid CNS availability after intranasal dosing, specific binding interactions, proteolytic processing to shorter fragments, and downstream effects on neurotrophic systems including BDNF protein levels in animal work. Functional effects can outlast intact peptide concentrations because of gene-expression and network-level changes.

Research applications

• nootropic and cognitive neuroscience
• ischemic stroke recovery research
• BDNF and neurotrophic signaling
• intranasal peptide delivery
• ACTH fragment structure-activity studies

Fields of active investigation, not claims. Investigation is not proof.

Neuropharmacology labs, stroke-research clinicians in regions where Semax was developed, and blood-brain-barrier delivery groups are the primary audiences. Cognitive-enhancement communities drive search traffic, but legitimate content should stay anchored to peer-reviewed neuroscience rather than lifestyle dosing culture.

Amounts reported in the literature

What published research and laboratory protocols document. These describe what was studied — they are not instructions, recommendations, or a protocol for use.

Handling and storage

Lyophilized Semax is stored refrigerated or frozen, dry and dark. Reconstituted nasal research solutions are kept cold; sterile technique matters because the route is mucosal.

Notes on combined research

Research comparisons often place Semax beside Selank (another Russian regulatory peptide) when mapping anxiolytic vs nootropic peptide tools. Stroke papers evaluate it as an add-on to standard care rather than as part of a multi-peptide lifestyle stack. BDNF-pathway discussions sometimes reference other neurotrophic strategies at the mechanistic level only.

Analytical specifications

Identity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.

Frequently asked questions

What is the dosage for Semax?
It depends which literature you mean. Acute stroke research used roughly 12–18 mg/day intranasally for several days. Secondary nootropic research discussions often cite a few hundred micrograms intranasally. Do not collapse those into one chart without labels.

How much BAC water for Semax?
For lyophilized powder, researchers pick a diluent volume that matches nasal spray or drop calibration—commonly 2–3 mL per multi-milligram vial. Some finished research preparations arrive already in solution.

Semax dosage per day?
Stroke-trial daily totals were in the low multi-milligram range. Cognitive research-chemical practice often discusses split intranasal mcg doses once or twice daily. Route in both cases is typically nasal, not subcutaneous.

Semax dosage chart?
A careful chart separates (1) animal mcg/kg data, (2) human stroke mg/day protocols, and (3) lower mcg secondary references. Mixing them without context creates false precision.

What is Semax half life?
The intact peptide is degraded quickly, yet behavioral or physiologic readouts in animal work can persist far longer, consistent with downstream neurotrophic signaling rather than continuous high plasma levels.

Can Semax be stacked?
Research discourse sometimes pairs it conceptually with Selank or standard stroke therapy. Controlled evidence for elaborate multi-peptide stacks is limited; combinations remain experimental.

Is Semax injected or nasal?
The dominant researched human route is intranasal. That is a major practical difference from most injectable research peptides on dosage pages.

Is Semax an approved drug everywhere?
It has an established research/clinical history in Russia and related literature. It is not broadly approved as a consumer nootropic in the United States; treat U.S. context as research-use education.

References

Every reference below resolves to an indexed paper. We would rather cite less and cite accurately.

• [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].
• Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
• [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].
• [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].

Research use only

For laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications. This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.